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RESUME 
 
Objectifs. Evaluer la prévalence de maladie coronarienne chez les patients diabétiques de type 2 
asymptomatiques ou avec angor atypique selon les recommandations américaines de l’American 
Diabetes Association et de l’American College of Cardiology. 
 
Méthodes. Cent cinquante-quatre patients diabétiques de type 2 asymptomatiques ou avec angor 
atypique et présentant au minimum 2 facteurs de risque cardio-vasculaires additionnels ont été 
dépistés par échocardiographie de stress (71%, n=109), scintigraphie myocardique de perfusion 
(26%, n=40) ou l’association des 2 examens (3%, n=5). 
   
Résultats. L’échocardiographie de stress s’est révélée positive chez 16 patients (14%) et 14 ont eu 
une coronarographie révélant des sténoses significatives chez 12 (86%). La scintigraphie 
myocardique de perfusion était positive chez 16 patients (36%). Huit patients ont eu une 
coronarographie et 4 (50%) présentaient des sténoses significatives. 
Au total, 31 patients (20%) ont montré des signes d’ischémie lors de l’examen non-invasif et 15 
(10%) ont présenté des sténoses significatives à la coronarographie. Les facteurs prédictifs 
indépendants de la maladie coronarienne étaient le tabagisme (OR 6.5, p=0.05), la 
microalbuminurie (OR 3.9, p=0.03), ainsi que les souffles fémoraux (OR 17.1, p=0.008). 
 
Conclusions. En suivant les recommandations américaines, un patient sur cinq présentait une 
ischémie lors des examens non-invasifs, tandis que 1 sur 10  avait des sténoses significatives à la 
coronarographie. L’analyse multivariée suggère que des marqueurs des complications micro- et 
macro-vasculaires en combinaison avec des facteurs de risque cardio-vasculaire classiques 
pourraient améliorer le pouvoir diagnostic de ces recommandations.
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SUMMARY 
 
Aims. We evaluated the prevalence of coronary artery disease in asymptomatic and atypical chest 
pain type 2 diabetic patients according to the American Diabetes Association and American College 
of Cardiology guidelines. 
 
Methods. Asymptomatic or atypical chest pain type 2 diabetic patients (n=154), with at least two 
additional cardiovascular risk factors, were screened for coronary artery disease using stress 
echocardiography (71%, n=109), myocardial perfusion imaging (26%, n=40) or both (3%, n=5). 
 
Results. Stress echocardiography was positive in 16 patients (14%) and 14 had a coronary 
angiography, revealing significant stenoses in 12 (86%). Myocardial perfusion imaging was 
positive in 16 patients (36%). Eight patients underwent angiography and 4 (50%) presented 
significant stenoses.   
Overall, 31 patients (20%) demonstrated signs of ischemia on non-invasive tests and 15 (10%) 
presented significant stenoses on coronary angiography. Independent predictors of coronary artery 
disease were smoking (OR 6.5, p=0.05), microalbuminuria (OR 3.9, p=0.03) and femoral murmur 
(OR 17.1, p=0.008).  
 
Conclusions. Following the guidelines, one in five diabetic patient presented ischemia on non-
invasive tests, while one in ten presented significant coronary stenoses. Multivariate analysis 
suggests that adding markers of micro- and macro-vascular complications to classical 
cardiovascular risk factors may enhance the diagnostic efficiency of the guidelines.
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INTRODUCTION 
 
Cardiovascular diseases are a major burden in the diabetic population as shown by large prospective 
epidemiological studies [1]. Coronary artery disease (CAD) remains the single most important 
cause of death associated with diabetes mellitus, with the mortality due to CAD being three times 
higher in diabetic patients than in non-diabetic patients [2]. Moreover, the risk of myocardial 
infarction in diabetic patients is similar to that of non-diabetic patients with a previous myocardial 
infarction [3]. These findings suggest that all type 2 diabetic patients should be considered from a 
secondary prevention perspective [3, 4]. Consequently, diabetic patients are now classified in the 
same high-risk category as that previously reserved for patients with known CAD [5, 6]. In 
addition, CAD is often silent in diabetic patients [7], thus contributing to the disease being 
undetected until acute complications, such as non-fatal myocardial infarction or sudden death, 
occur. The systematic screening for diabetic retinopathy and nephropathy has been shown to be 
efficient in reducing these microvascular complications. Paradoxically, to date, there has been no 
studies on the efficiency of systematic screening for coronary disease in diabetic patients for the 
reduction of cardiovascular mortality and morbidity [8]. Early and systematic screening for CAD 
may decrease the morbidity and mortality seen in this very high-risk population. Several expert 
groups have published recommendations over the last years for the screening of coronary artery 
disease in the diabetic population. The first guidelines were published by the French Diabetes 
Association (ALFEDIAM) in 1995 and recommend screening asymptomatic type 2 diabetic 
patients with at least one additional cardiovascular risk factor [9]. The American Diabetes 
Association and the American College of Cardiology (ADA-ACC) published a set of guidelines in 
1998 and recommend screening asymptomatic type 2 diabetic patients with at least two additional 
cardiovascular risk factors [10]. In 2000, the Swiss guidelines [11] were published and these are 
based on the American guidelines. Despite these recommendations, few studies have been 
conducted to investigate their diagnostic efficiency, as defined by the proportion of the patients 
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found to present CAD. This prospective study addresses this issue by using the ADA-ACC 
guidelines to assess the prevalence of abnormal non-invasive tests and significant CAD in 
asymptomatic type 2 diabetic patients and in those with atypical chest pain. 
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PATIENTS AND METHODS 
 
Patients. Between February 1998 and July 2002, 154 consecutive Caucasian type 2 diabetic 
patients without history of CAD and with either no chest pain (n=113, 73%) or atypical chest pain 
(n=41, 27%) were prospectively screened for CAD using stress echocardiography or myocardial 
perfusion imaging. Chest pain was defined according to the Rose questionnaire. Patients with 
typical angina pectoris, a history of CAD or ECG modifications were excluded from the study. 
Moreover, all the patients needed to have at least two additional cardiovascular risk factors to be 
included in the study, as stated in the ADA-ACC guidelines [10]. These patients were recruited and 
followed-up in an ambulatory setting at the diabetology clinic of the Lausanne University Hospital, 
Switzerland. The study complies with the Swiss CAD screening guidelines in diabetic patients and 
all patients gave their informed consent to participate in the screening tests. 
 
Screening algorithm. Enrolled patients were screened for the presence of coronary artery disease 
according to the ADA-ACC guidelines [10]. Of the 154 patients qualifying for screening, all 
echogenic patients (n=109, 71%) underwent stress echocardiography (SE), while non-echogenic 
patients (n=40, 26%) were referred for myocardial perfusion imaging (MPI) and 5 (3%) had both 
tests. Patients demonstrating a moderate or large area of myocardial ischemia (≥ 2 segments) on SE 
or MPI were referred for coronary angiography (CA). When ischemia was limited to a small area (< 
2 segments), no angiogram was performed in accordance with the ADA-ACC guidelines [10]. 
 
Stress echocardiography (SE). Two-dimensional transthoracic echocardiographic images were 
obtained from the standard parasternal and apical windows before, during, and after stress. All 
images were recorded in a digital quad-screen format for simultaneous visualisation of wall motion. 
Dobutamine (3 min stages of 10, 20, 30 and 40 µg · kg-1 · min-1) was the preferred stress agent 
(n=87, 76%). Dobutamine stress was considered maximal if 85% of the maximal predicted heart 
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rate for age was reached. If this endpoint was not reached, atropine was added in 4 fractionated 
doses of 0.25 mg each minute, up to a maximal cumulative dose of 1 mg. Dipyridamole was used as 
an alternate pharmacological stress agent in patients with contraindications to dobutamine (e.g. 
severe hypertension or supraventricular tachycardia). Dipyridamole was injected intravenously at a 
dose of 0.56 mg · kg-1 over 4 minutes followed by 4 minutes of observation and then, if negative, 
followed by 0.28 mg · kg-1 over 2 minutes. At the end of the perfusion, atropine was added up to 1 
mg.  Standard 12-lead ECG and blood pressure were continuously monitored throughout the test. 
All images were interpreted by two experienced observers and discrepancies were resolved by 
consensus. The left ventricular wall was divided into 16 segments according to the 
recommendations of the American Society of Echocardiography [12]. The test was considered 
positive for the presence of ischemia if new onset or worsening wall motion abnormalities appeared 
during stress compared to rest. The test was suggestive of previous myocardial infarction if wall 
motion abnormalities were present both at rest and during stress. 
 
Single photon emission computed tomography myocardial perfusion imaging (SPECT-MPI).  
We used a conventional 1-day protocol with either dual-isotope Tl-201 at rest (111MBq) and Tc-
99m-MIBI (Sestamibi) during stress (925MBq) in lean subjects or with single-isotope Tc-99m-
MIBI (370MBq for stress, 925MBq for rest) in more corpulent subjects (BMI ≥ 30 kg·m-2). SPECT 
studies were performed on a dual-headed gamma camera (Siemens E.-Cam, Siemens, Erlangen, 
Germany) using low-energy, high-resolution parallel-hole collimators. Resting studies began 10-15 
minutes after the rest Tl-201 or Tc-99m-MIBI injection, and stress imaging started 30-45 minutes 
after the stress Tc-99m-MIBI injection. Exercise testing was performed with a modified-Bruce 
protocol on a bicycle-ergometer (n=20, 44%) using 2-minute step increments (25 or 30W) in order 
to reach 85% of the maximal predicted heart rate for age. In patients unable to perform a complete 
exercise test (n=25, 56%), pharmacological stress testing was performed using a 4-minute 
dipyridamole infusion (0.56 mg · kg-1), eventually completed by some low dose exercise (isometric 
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handgrip or 25-60 W bicycle stress) to alleviate side effects of dipyridamole. The radionuclide 
tracer was injected at peak exercise that was maintained at least 1, preferably 2 minutes. For 
pharmacological stress, the tracer injection was performed 3 minutes after the end of dipyridamole 
infusion. At least one hour separated both stress and rest studies. Standard 12-lead ECG and blood 
pressure measurements were recorded every 2 minutes during stress and recovery. Two experienced 
readers evaluated rest and stress images as well as ECG-gated cine images. Discrepancies were 
resolved by consensus. Regional radiotracer distributions were analysed visually on short-, 
horizontal- and vertical-long axis views as well as semi-quantitatively on polar maps using the 
Emory Cardiac Toolbox software [13]. Stress-induced ischemia was defined as moderate or greater-
than-moderate improvement of regional perfusion on rest images as compared to stress images. A 
myocardial scar was considered when the perfusion abnormalities remained unchanged between 
stress and rest. 
 
Coronary angiography (CA). Coronary angiography was performed transcutaneously through one 
of the femoral arteries. Significant coronary stenoses were defined as a narrowing in the cross-
sectional area of more than 70% of any of the 3 major coronary arteries and of ≥ 50% on the left 
main coronary artery. CAD was diagnosed if one or more coronary stenoses were found at CA. The 
angiograms were reviewed by 2 experienced observers and discrepancies were resolved by 
consensus. No serious complications during and after coronary angiography were reported. 
 
Clinical data. Type 2 diabetes was defined according to the World Health Organization criterias 
[14]. Hypertension was diagnosed if the patient was receiving antihypertensive drugs or if blood 
pressure at rest was higher than 135/85 mmHg on two occasions. Dyslipidemia was recognized if 
the patient was taking lipid-lowering drugs, if triglycerides were above 2.2 mmol/l or if at least two 
of the following criteria were present : total cholesterol > 5.0 mmol/l, LDL > 3.0 mmol/l, HDL < 
0.9 mmol/l, total cholesterol / HDL ratio > 5.0. Microalbuminuria was diagnosed when the ratio 
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albumin to creatinine in a morning urinary spot was ≥ 2.5 mg/mmol for men and ≥ 3.5 mg/mmol for 
women. Macroalbuminuria was diagnosed if urinary albumin excretion was above 300 mg per day. 
Abdominal obesity was present if the waist to hip ratio was above 0.85 for women and 0.90 for 
men. 
 
Statistical analyses. Continuous variables, normally distributed, were expressed in means with 
standard deviation and the Student’s t test was used for comparisons. Non-normally distributed 
continuous variables were expressed as median, with 10th - 90th percentiles and the Mann-Whitney 
U test was used for comparisons. Categorical variables were expressed in frequency and differences 
were based on the chi-square test. For statistical purposes, the presence of coronary artery disease 
was defined as a positive SE or SPECT-MPI in the absence of coronary angiography or as the 
presence of at least one significant coronary stenosis on CA. Forward stepwise logistic regression 
analysis was performed to determine independent predictors of CAD. The 10-years absolute 
cardiovascular risk was calculated using the Framingham equation [15]. All statistical analyses 
were performed using JMP 5.0 (SAS Institute, Cary, USA) and a p value ≤ 0.05 was considered 
statistically significant. 
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RESULTS 
 
One hundred fifty-four type 2 diabetic patients without history of CAD and with either no chest 
pain (n=113, 73%) or atypical chest pain (n=41, 27%) were screened according to the guidelines of 
the ADA-ACC. The patients’ clinical characteristics are shown in Table 1. Patients were mostly 
males (67%) with a mean age of 60 years and a median diabetes duration of 7 years. Among the 
cardiovascular risk factors, hypertension, dyslipidemia and abdominal obesity were highly 
prevalent (79%,  84% and 97%), micro/macro-albuminuria was present in 36% and 37% were 
currently smokers. The median Framingham 10-years absolute cardiovascular risk was 23%.  
 
Stress echocardiography. Stress echocardiography was performed in 114 patients and was positive 
in 16 (14%): 7 (44%) patients presented only ischemia, 6 (37%) had ischemia and evidence of a 
previous silent myocardial infarction and another 3 (19%) demonstrated evidence of silent 
myocardial infarction without ischemia (Figure 1). Coronary angiography was performed in 14 of 
the 16 patients with a positive SE. The 2 remaining patients had minor echocardiographic 
abnormalities (no angiography performed according to the guidelines). Significant stenoses were 
observed in 12 of these 14 patients (86%): 5 patients had 3-vessel disease, 3 had 2-vessel disease 
and 4 had single-vessel disease (Figure 1). The positive predictive value of SE to detect significant 
coronary stenoses was estimated to be 86% (CI: 0.60 - 0.96). 
 
SPECT-MPI. Myocardial perfusion imaging was performed in 45 patients and was abnormal in 16 
(36%): in 13 (81%) patients only ischemia was observed, 2 (13%) had ischemia and evidence of 
previous silent myocardial infarction and 1 (6%) demonstrated evidence of previous silent 
myocardial infarction without ischemia (Figure 1). Coronary angiography was performed in 8 of 
these patients and revealed significant stenoses in 4 (50%) (Figure 1). The angiogram showed 2-
vessel disease in 3 patients and single-vessel disease in 1. We did not observe any 3-vessel disease. 
 Page 13 
  
The 8 remaining patients did not undergo CA (refusal n=2, minimal perfusion defects confined to 
one segment n=6). The positive predictive value of SPECT–MPI to detect angiographically 
significant coronary stenoses was calculated to be 50% (CI: 0.22 - 0.78). 
 
Overall results of non-invasive tests. Non-invasive tests were positive in 31 patients (20%), with 
15 (10%) presenting significant stenoses at coronary angiography. Five patients had both tests and 
the results were concordant: 4 had both screening tests negative, while one patient had both exams 
positive. Table 2 shows univariate predictors for the presence of CAD. Patients presenting atypical 
chest pain did not have a higher risk of presenting a positive screening test. Markers of vascular 
complications were found to be the main factors associated with the presence of CAD: carotid and 
femoral murmurs for macrovascular disease, and micro/macro-albuminuria, diabetic retinopathy 
and erectile dysfunction for microvascular disease. It is worth noting that hypertension and 
dyslipidemia did not predict CAD in our population. Independent predictors of CAD in forward 
stepwise logistic regression were femoral murmur, microalbuminuria and smoking (Table 3). 
 
CAD prediction score. The results of the multivariate analysis were used to create a composite 
score for predicting the presence of CAD. One point was assigned for each of the three former 
independent predictors found (smoking, micro-/macro-albuminuria and femoral murmur). One 
point was assigned to each because of the arbitrary need to have a simple equation. In a receiver 
operating characteristic analysis this score was able to satisfactorily predict the presence of CAD in 
this population with an area under the curve of 0.74 (CI: 0.67 – 0.81, p < 0.001).  
 
Treatment of patients with established CAD. The subsequent management of the 15 patients 
presenting with significant stenoses at coronary angiography is shown in Table 4. Fifty-four percent 
of these patients (n=8) underwent invasive revascularization procedures, which included coronary 
artery bypass grafting and coronary angioplasty. 
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DISCUSSION 
 
This study evaluates, for the first time, the efficiency of the ADA-ACC guidelines for the screening 
of CAD in asymptomatic or atypical chest pain type 2 diabetic patients. Systematic screening for 
CAD with SE or SPECT-MPI found that 20% of the patients had a positive screening test. 
Subsequently, coronary angiography identified significant stenoses in 10% of the patients leading to 
slightly more than half of them (54%) undergoing subsequent revascularization procedures. 
 
The results of this study are consistent with previous data from the literature using different CAD 
screening guidelines. Janand-Delenne et al. [16] conducted a similar study following the 
ALFEDIAM guidelines [9] using stress ECG and SPECT-MPI in asymptomatic type 1 and 2 
diabetic patients. They found a 15% prevalence of abnormal screening tests across both patient 
groups. However when only the type 2 diabetic patients were considered, the prevalence rose to 
18.4%. Furthermore, the prevalence of coronary stenoses ≥ 50% was 9.6%, despite the fact that 
coronary angiography was refused by 6 of 32 patients. In an other study with a similar design, 
Torremocha et al. reported abnormal non-invasive studies (stress ECG and SPECT-MPI) in 11.1% 
of the patients, with significant stenoses in 9.7% [17]. In type 2 diabetic patients, De Lorenzo et al., 
using SPECT-MPI as a screening test, observed a 26% prevalence of abnormal perfusion scans, 
with abnormal scans being predictive of future cardiac events [18]. Despite some variability in the 
prevalence of CAD in the previous and other studies [19-24], likely to be due to differences in 
patient selection criteria, ethnic groups, screening algorithms and screening tests, our findings are in 
agreement. However, when Paillole et al. performed systematic coronary angiographies in all of 
their 59 diabetic patients without known CAD, but with typical and atypical chest pain or ST 
modifications, they found a 34% prevalence of significant stenoses at coronary angiography [25]. 
Despite the fact that their population was at higher risk due to the presence of typical angina or ST 
segment abnormalities in some patients, this would indicate that the 10% prevalence of significant 
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stenoses found in our study could only constitute a lower limit. Indeed, because the sensitivity of 
stress echocardiography and SPECT-MPI is around 80% to 84% [26], 16 to 20% of the patients 
theoretically have a false negative non-invasive test, leading to an underestimation of the 
prevalence of significant stenoses. In our study, 54% of the patients with significant stenoses and 
5% of the screened population were revascularized. In the previously mentioned studies by Janand-
Delenne et al. and Torremocha et al. [16, 17], respectively 37% and 43% of the patients presenting 
with significant stenoses underwent revascularization procedures. 
 
In our study, both stress echocardiography and myocardial perfusion imaging were used as 
screening methods for the detection of ischemia. According to the literature, both methods have 
comparable sensitivity and specificity [26]. Interestingly, the prevalence of positive screening tests 
was 2.5-fold higher in the SPECT-MPI group as compared to the SE group (36% vs. 14%, p = 
0.002). This significant difference questions the relative value of each technique for the detection of 
CAD in diabetic patients. Despite the lack of studies comparing these two tests in this population, 
some elements suggest that these two methods do not necessarily provide the same information. 
The first evidence is related to the different detection techniques these two tests use to diagnose 
ischemia. SPECT-MPI evaluates the differential increase in regional myocardial perfusion to a 
physical or pharmacological stress, which depends on both coronary epicardial and 
microcirculatory blood flow. In contrast, stress echocardiography analyses changes in systolic 
function (wall motion and contractility) during stress. The flow redistribution seen as regional 
differences in perfusion on SPECT-MPI, leading to oxygen supply and demand imbalance, happens 
earlier in the ischemic cascade than systolic dysfunction observed with stress echocardiography [26, 
27]. The second important difference between these two tests is inherent to their relative threshold 
for the detection of ischemia. Stress echocardiography has a relatively high threshold, as it requires 
at least 20% of the myocardial thickness and 5% of ventricular mass to be ischemic before 
anomalies in systolic function can be detected [28]. Therefore a small area of ischemia caused by 
 Page 16 
  
distal vessel disease, such as seen in diabetes, may not be visualized on SE [29]. In contrast, 
SPECT-MPI is a very sensitive technique that can visualize, if microvascular disease is present, an 
inhomogeneity or maldistribution of myocardial blood flow not inducing yet any alteration of 
contractility. Such perfusion abnormalities are frequently observed in high-risk patients and are 
related to a diminished coronary flow reserve. Indeed, decrease in intracoronary fractional flow 
reserve has been shown to be associated with reversible defects on SPECT-MPI [30-32]. This also 
explains the lower positive predictive value found in our study of SPECT-MPI to detect 
angiographically significant coronary stenoses compared to SE (SPECT-MPI 50% CI:22-78 vs. SE 
86% CI:60-96, p = NS). At first, abnormal SPECT-MPI were not associated with significant 
coronary stenoses and were considered as false positive. However, in term of microcirculatory 
status, several studies suggest that some of these may actually be true positive. Kaul et al. [33] 
reported that 35% of abnormal scans were related to the presence of non-occlusive (<50%) 
coronary stenoses, thus suggesting a possible underestimation of the coronary obstruction. 
Moreover, Verna et al. [34] demonstrated occult atherosclerotic plaques and an abnormal 
vasodilatory capacity, in respectively, 95% and 80% of the patients with angiographically “normal” 
coronary arteries and reversible defects on SPECT-MPI using intravascular ultrasonography and 
doppler. This suggests that non-significant epicardial stenoses and microvascular dysfunction are 
often combined and may have an additive effect leading to a further reduction on coronary flow 
reserve. 
 
Markers of macro- and micro-vascular complications, such as femoral murmur and 
microalbuminuria were found to be the main predictors of coronary artery disease in our study. 
Classic cardiovascular risk factors, such as hypertension and dyslipidemia, were not predictive of 
CAD. This was found in other studies and could be related to their high prevalence in the studied 
population, which has been shown to reduce discriminative power [16, 17]. In the DIAD study [35], 
performed in asymptomatic type 2 diabetic patients, the cardiovascular risk factors were not 
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discriminative either. In addition, the Framingham 10-years absolute cardiovascular risk did not 
predict the presence of CAD in this population, a finding also observed in the study by Torremocha 
et al. [17]. These observations suggest that all cardiovascular risk factors do not have the same 
strength to predict CAD and therefore their respective importance in the guidelines should be 
reassessed. Markers of micro- and macro-vascular damage, such as microalbuminuria and the 
presence of atherosclerosis in the peripheral vasculature, in combination with some cardiovascular 
risk factors, such as smoking, could be helpful to select a subgroup of patients with a higher CAD 
probability. Thus a group in whom screening strategies could prove to be more efficient and cost-
effective.  
 
Following current guidelines, the number of patients needed to be screened (NNS) to find one 
patient with a positive non-invasive test was 5, the NNS to detect one patient with significant 
coronary stenoses was 10 and the NNS for one patient to benefit from revascularization was 20. The 
cost of these non-invasive screening tests is important, yet, since a significant proportion of patients 
did benefit from revascularization, a significant decrease in mortality and morbidity is expected. 
This is presently studied by the BARI 2D trial [36] which is an ongoing multicenter study 
evaluating the effect of early revascularization procedures in reducing mortality and morbidity in 
type 2 diabetic patients with mild and stable cardiac symptoms. 
 
Finally, as R.W. Nesto suggested [8], the justification for screening depends of whether detection of 
CAD leads to treatment strategies that ultimately reduce cardiovascular morbidity and mortality.  
 
 
Limitations of the study. Studies with a larger number of patients are necessary to corroborate our 
results. Furthermore, we possibly underestimated the true prevalence of coronary artery disease in 
our population, because angiography was not performed in all patients with ischemia on non-
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invasive tests (ischemia limited to 1 segment and in those who refused). Detection of occult 
atherosclerotic plaques by intravascular ultrasound and measurement of the fractional flow reserve 
would have been useful to observe whether abnormal non-invasive tests in patients without 
significant stenoses were true or false positive. All diabetic patients were recruited from a tertiary 
diabetic referral centre supposedly having more complicated patients therefore our results might not 
be extended to the diabetic population in general. Finally, our results cannot be extended further to 
type 1 diabetes because of the different physiopathology and cardiovascular risk factors found in 
this population. It would have been interesting to follow-up the studied population for the 
occurrence of cardiovascular events in order to determine the prognostic impact of this screening 
strategy. 
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Figure 1. Overview of the screening results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legends 
 
SE : Stress Echocardiography, SPECT-MPI : Single Photon Emission Computed 
Tomography, CA : Coronary Angiography 
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Table 1. Clinical characteristics of diabetic subjects (n = 154) 
 
Male gender 67 % 
Age (years) 60 ± 9 
Asymptomatic 73 % 
Atypical chest pain 27 % 
Exertional dyspnea 27 % 
Claudication 13 % 
Diabetes duration (years) 7 (2-22) 
Smoking / stopped / never smoked 37% / 28% / 35 % 
Hypertension 79 % 
Dyslipidemia 84 % 
Micro/macro-albuminuria 36 % 
Familial history of CAD 32 % 
Abdominal obesity 97 % 
Framingham’s 10-years absolute CV risk 23 % (11-37) 
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Table 2. Univariate predictors of CAD (n = 154) 
 
 CAD + CAD - OR P 
Male gender 83 % 64 % 2.4 0.07 
Age (years) 60 ± 8 60 ± 9 - NS 
Diabetes duration (years) 8 (2-22) 7 (2-22) - NS 
Atypical chest pain 25 % 27 % 0.9 NS 
Exertional dyspnea 46 % 23 % 2.3 0.02 
 
Cardiovascular risk factors 
Hypertension 79 % 79 % 1.0 NS 
Dyslipidemia 88 % 83 % 1.4 NS 
Smoking 88 % 62 % 3.6 0.01 
Familial history of CAD 47 % 30 % 1.9 0.13 
Micro/macro-albuminuria 55 % 32 % 2.2 0.05 
Abdominal obesity 100 % 96 % - NS 
Physical inactivity 56 % 58 % 0.9 NS 
Framingham 10yrs absolute CV risk 26 % (12-37) 22 % (11-35) - NS 
Number of CV risk factors 5 (3-6) 4 (2-6) - 0.009 
 
Clinical examination 
Carotid murmur 14 % 5 % 2.2 0.15 
Claudication 24 % 11 % 2.0 0.12 
Peripheral pulses absent 48 % 27 % 2.1 0.05 
Femoral murmur 27 % 5 % 3.8 0.001 
Diabetic proliferative retinopathy 29 % 7 % 3.5 0.002 
Erectile dysfunction 58 % 24 % 3.2 0.004 
Systolic blood pressure (mmHg) 146 ± 20 143 ± 17 - NS 
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Diastolic blood pressure (mmHg) 87 ± 13 87 ± 10 - NS 
Body mass index (kg/m2) 29.2 ± 4.7 30.1 ± 5.6 - NS 
Waist-hip ratio 1.02 ± 0.05 0.98 ± 0.07 - 0.06 
  
Laboratory values 
HbA1c (%) 8.2 (6.8-11.4) 8.4 (6.4-12.9) - NS 
Total cholesterol (mmol/l) 5.6 ± 1.4 5.7 ± 1.2 - NS 
HDL cholesterol (mmol/l) 1.2 ± 0.3 1.2 ± 0.4 - NS 
LDL cholesterol (mmol/l) 3.3 ± 1.1 3.5 ± 1.0 - NS 
Triglycerides (mmol/l) 2.0 (0.9-3.3) 2.0 (1.2-4.0) - NS 
Creatinine clearance (ml/min) 87 (65-113) 87 (56-131) - NS 
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Table 3. Stepwise model of independent predictors of CAD 
 
 OR P 
Micro/macro-albuminuria 3.9 0.03 
Smoking 6.5 0.05 
Femoral murmur 17.1 0.008 
Gender - 0.70 
Age - 0.56 
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Table 4. Management of the patients with established CAD (n=15) 
 
Medical treatment only 7 (47%) 
Coronary artery bypass grafting 4 (27%) 
Percutaneous transluminal coronary angioplasty 4 (27%) 
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